Article
Chemistry, Multidisciplinary
Jing-Jun Nie, Yanli Liu, Yu Qi, Nasha Zhang, Bingran Yu, Da-Fu Chen, Ming Yang, Fu-Jian Xu
Summary: A new charge-reversal vehicle system was proposed for treating hepatocellular carcinoma (HCC), showing high anti-tumor efficiency and potential for improving HCC therapy and combination treatment. The system exhibited promising possibilities for treating other liver diseases as well.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Genetics & Heredity
Yuping Bai, Wenbo Qi, Le Liu, Jing Zhang, Lan Pang, Tiejun Gan, Pengfei Wang, Chen Wang, Hao Chen
Summary: This study constructed seven prognostic markers related to HCC survival. Patients were divided into high and low risk groups, with significant differences between them shown in KM curve analysis. Stratified analysis revealed significant differences in risk values among different ages, genders, stages, and grades, which could serve as independent predictors.
FRONTIERS IN GENETICS
(2021)
Article
Pharmacology & Pharmacy
Anurag Kumar Gautam, Pranesh Kumar, Biswanath Maity, Ganesh Routholla, Balaram Ghosh, Kumarappan Chidambaram, M. Yasmin Begum, Adel Al Fatease, P. S. Rajinikanth, Sanjay Singh, Sudipta Saha, M. R. Vijayakumar
Summary: This study synthesized a synthetic version of DL and developed DL nanoparticles, demonstrating their high therapeutic effectiveness against HCC. In vivo pharmacokinetics and bio-distribution experiments revealed that DL nanoparticles outperformed pristine DL in terms of pharmacokinetic performance and targeted delivery. In vitro experiments also confirmed the strong apoptotic properties of DL against HCC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Zhirui Zeng, Shan Lei, Jingya Wang, Yushi Yang, Jinzhi Lan, Qianting Tian, Tengxiang Chen, Xiaojiang Hao
Summary: Hypoxia promotes the progression of hepatocellular carcinoma by changing gene expression profiles, and the study identified a three-gene signature (CFHR3, EGLN3, and CHGA) with prognostic value for HCC patients. Overexpression of CFHR3 may be a potential strategy to treat HCC and overcome hypoxia.
Article
Chemistry, Multidisciplinary
Aftab Ullah, Marina Khan, Yibang Zhang, Faisal Raza, Muhammad Hasnat, Jin Cao, Xueyong Qi, Abid Hussain, Daojun Liu
Summary: This study developed hollow mesoporous organosilica nanoparticles (HMONs) with a thioether-hybrid structure for starvation and apoptosis therapy of HCC. The HMONs were surface modified to yield CCM-coated HMONs (TSBRs) with enhanced cell uptake and cytotoxicity. The TSBRs exhibited excellent catalytic activity and effectively reduced tumor size and weight in both in vitro and in vivo settings. The NPs showed long-term safety in vivo. This study demonstrates the anti-cancer potential of TSBRs for HCC treatment.
PHARMACEUTICAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Ashuai Du, Shiqin Li, Yuzheng Zhou, Cyrollah Disoma, Yujie Liao, Yongxing Zhang, Zongpeng Chen, Qinglong Yang, Pinjia Liu, Sixu Liu, Zijun Dong, Roona Razzaq, Siyi Tao, Xuan Chen, Yuxin Liu, Lunan Xu, Qianjun Zhang, Shanni Li, Jian Peng, Zanxian Xia
Summary: This study identified a new oncogenic circRNA, circMDK, that promotes the progression of HCC through the regulation of the miR-346/874-3p-ATG16L1 axis. The research team also developed poly (beta-amino esters)-based nanoparticles that effectively deliver siRNA targeting circMDK, inhibiting HCC proliferation and metastasis.
Review
Biochemistry & Molecular Biology
Divya Sharma, Sanjay Arora, Jagdish Singh, Buddhadev Layek
Summary: Gene therapy aims to transfer genetic materials into targeted cells for disease treatment or prevention. Nonviral vectors have gained attention for their safety, payload capacity, and stealth abilities, but face challenges in overcoming intracellular and extracellular barriers. This review highlights current advancements in nonviral gene delivery systems and their future potential.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)
Review
Gastroenterology & Hepatology
Lorenza Rimassa, Richard S. Finn, Bruno Sangro
Summary: Single-agent immune checkpoint inhibitors (ICIs) have limited efficacy in advanced hepatocellular carcinoma (HCC) patients, and approximately 30% of patients show intrinsic resistance to ICIs. Therefore, researchers are exploring combination therapies, such as anti-angiogenic agents and other ICIs. Some trials have shown promising results and potential for clinical application. However, there are still many unanswered questions that require further research.
JOURNAL OF HEPATOLOGY
(2023)
Review
Medicine, Research & Experimental
Mingzhen Zhou, Baorui Liu, Jie Shen
Summary: Hepatocellular carcinoma (HCC) is a common malignancy with late-appearing symptoms, making diagnosis and treatment challenging. Immunotherapy, including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies, has emerged as a new hope for HCC treatment by regulating the immune system to target liver cancer cells.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Review
Chemistry, Multidisciplinary
Cheng Yu, Long Li, Pei Hu, Yan Yang, Wei Wei, Xin Deng, Lu Wang, Franklin R. Tay, Jingzhi Ma
Summary: Gene therapy presents a promising approach for treating genetic disorders, but challenges remain with viral vectors. The emergence of nanomedicine has revolutionized the field of gene therapy, with recent advancements in stimulus-responsive nonviral nanocarriers showing high efficiency in delivering therapeutic nucleic acids.
Article
Biochemistry & Molecular Biology
Chalermsin Permtermsin, H. Lalchungnunga, Sirintra Nakjang, John Casement, Laura Frances Ogle, Helen L. L. Reeves, Gordon Strathdee, Ruchi Shukla
Summary: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. Current treatments are not effective and have significant side effects. A new method using bioinformatics has been developed to identify genes that are necessary for the survival of specific molecular subgroups of HCC but not normal cells. By targeting these genes, it may be possible to induce synthetic lethality in cancer cells. One gene, TIAM1, has been identified as a potential therapeutic target in a specific subgroup of HCC patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Cell Biology
Dafeng Xu, Yu Wang, Jincai Wu, Yuliang Zhang, Zhehao Liu, Yonghai Chen, Jinfang Zheng
Summary: This study identified 64 common DEIGs enriched in tumor immunologic related signaling pathways and constructed a 5-gene signature risk model to predict the prognosis of HCC patients. Different immune expression characteristics lead to different prognostic outcomes. The model showed better performance compared to existing ones and had strong robustness across different cohorts.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Baasansuren Selenge, Shinichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saito, Chie Takasu, Hiroki Teraoku, Mitsuo Shimada
Summary: This study investigated the impact of L-type amino acid transporter 3 (LAT3) expression on the prognosis of hepatocellular carcinoma (HCC). The results demonstrated that LAT3 expression was associated with poor prognosis of HCC and high p-AKT expression.
Article
Nanoscience & Nanotechnology
Xue Gong, Jingliang Wu, Jiaxuan Wen, Xueying Ding, Na Xu, Mengmeng Sun, Guohua Yu, Shuzhen Liu, Bo Zhang, Hongying Liu
Summary: In this study, nanoscale dual-ligand-modified multifunctional liposomes (CMDLs) were prepared for the codelivery of curcumin and metformin to inhibit the cross-talk between tumor cells and hepatic stellate cells (HSCs). The results showed that CMDLs effectively enhanced drug internalization and retention, leading to a greater proapoptotic effect. Furthermore, the in vivo studies demonstrated that CMDLs exhibited superior anti-HCC efficacy by reducing extracellular matrix deposition, inhibiting tumor angiogenesis, and blocking HCC metastasis.
ACS APPLIED NANO MATERIALS
(2022)
Article
Biotechnology & Applied Microbiology
Xuqi Peng, Gan Lin, Yun Zeng, Zhao Lei, Gang Liu
Summary: Hepatocellular carcinoma is associated with poor prognosis, but early-stage patients have better survival rates. Mesoporous silica nanoparticles-based imaging agents have emerged as a promising tool for early detection of HCC, offering potential applications in clinical settings despite some challenges to overcome. Multi-modal imaging systems have been developed for enhanced spatial resolution and sensitivity.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2021)
